Trulicity

Type 2 Diabetes Management

Trulicity is used to help manage blood sugar levels in adults and children 10 years of age and older with type 2 diabetes mellitus. It is meant to be used in combination with a healthy diet and regular exercise. By helping the body release insulin and slowing digestion, it assists in keeping blood glucose within a target range.

Cardiovascular Risk Reduction

For adults with type 2 diabetes, Trulicity is also prescribed to reduce the risk of major cardiovascular events, such as:

• Heart attack
• Stroke
• Death related to heart or blood vessel problems

This application is intended for patients who either have established cardiovascular disease or possess multiple risk factors for heart problems, such as high blood pressure or high cholesterol.

Important Limitations

Trulicity is not suitable for everyone with blood sugar issues. It is not used for the following:

• Type 1 diabetes: It is not a substitute for insulin and does not treat type 1 diabetes.
• Diabetic ketoacidosis: It should not be used to treat this life-threatening complication of diabetes.
• Weight loss: While some patients may experience weight loss as a side effect, Trulicity is not specifically approved as a weight-management medication.

How Trulicity Affects the Body

Trulicity belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. It acts like a hormone that occurs naturally in the body to help manage blood sugar levels in several ways:

• Stimulating Insulin: When blood sugar levels rise, such as after a meal, Trulicity prompts the pancreas to release insulin. Insulin helps move sugar from the blood into the cells for energy.
• Reducing Liver Sugar: It helps stop the liver from making and releasing too much sugar into the bloodstream by suppressing the hormone glucagon.
• Slowing Digestion: It slows down the process of food leaving the stomach, a process called gastric emptying. This helps prevent blood sugar levels from rising too quickly after eating and can help you feel full for a longer period.
• Appetite Regulation: By affecting the brain's hunger signals and slowing digestion, it may lead to a decrease in appetite.

Because Trulicity primarily triggers insulin release when blood sugar is high, it has a lower risk of causing dangerously low blood sugar (hypoglycemia) compared to some other diabetes medications when used on its own.

Common Side Effects

The most frequent side effects associated with Trulicity involve the digestive system. These symptoms are often most noticeable when starting the medication or after a dose increase. Common side effects include:

• Nausea and vomiting
• Diarrhea
• Abdominal pain
• Decreased appetite
• Indigestion or upset stomach
• Fatigue

Serious Side Effects

Though rare, some side effects can be severe. Seek medical help immediately if you experience any of the following:

• Pancreatitis: Severe, persistent pain in the stomach area that may radiate to the back.
• Kidney issues: New or worsening kidney failure, which may be caused by dehydration from nausea and diarrhea.
• Gallbladder problems: Symptoms such as upper stomach pain, fever, and clay-colored stools.
• Low blood sugar (hypoglycemia): This risk increases if Trulicity is used with other diabetes drugs like insulin or sulfonylureas.
• Severe allergic reactions: Symptoms include swelling of the face or throat, rash, fainting, or rapid heartbeat.
• Vision changes: New or worsening blurred vision or other changes in sight.

Contact a doctor if you notice a lump or swelling in the neck, trouble swallowing, or persistent hoarseness.

Thyroid Tumor Risk

Trulicity has a boxed warning because it caused thyroid tumors in animal studies. It is unknown if it causes these tumors in humans. This medication should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Symptoms such as a lump or swelling in the neck, hoarseness, or trouble swallowing should be monitored.

Pancreatitis

Inflammation of the pancreas (pancreatitis) has been reported in patients using GLP-1 receptor agonists like Trulicity. If persistent, severe abdominal pain occurs—which may radiate to the back and may be accompanied by vomiting—the medication should be stopped and medical attention sought immediately.

Hypoglycemia

The risk of low blood sugar (hypoglycemia) is increased when Trulicity is used in combination with insulin or insulin secretagogues, such as sulfonylureas. A lower dose of these concurrent medications may be required to reduce this risk.

Kidney and Digestive Issues

Trulicity can cause severe gastrointestinal side effects, including nausea, vomiting, and diarrhea. These reactions can lead to dehydration, which may cause or worsen acute kidney injury. It is not recommended for patients with severe gastrointestinal disease, such as gastroparesis. Monitoring kidney function is important, especially when starting the drug or increasing the dose.

Other Precautions

• Hypersensitivity: Serious allergic reactions, including anaphylaxis and angioedema, have occurred. If a reaction is suspected, the medication must be discontinued.
• Diabetic Retinopathy: Rapid improvements in blood sugar control can lead to a temporary worsening of diabetic retinopathy. Patients with a history of this condition should be monitored.
• Gallbladder Disease: Acute gallbladder problems, such as gallstones or inflammation, have been reported.
• Suicidal Thoughts: While recent FDA evaluations have not found a clear link between GLP-1 medications and suicidal thoughts or actions, healthcare providers typically monitor for changes in mood or behavior.

Pregnancy

Research on the effects of Trulicity (dulaglutide) in pregnant women is limited. In animal studies, the medication was associated with adverse effects on fetal development, such as reduced birth weight and skeletal changes. Consequently, Trulicity is typically only recommended during pregnancy if the potential benefit to the mother clearly justifies the risk to the fetus.

Because Trulicity remains in the system for several weeks, healthcare providers often suggest discontinuing the medication at least two months before a planned pregnancy. It is important to discuss blood sugar management alternatives with a clinician if you are pregnant or planning to conceive.

Breastfeeding

It is not yet known if Trulicity passes into human breast milk or what effects it may have on a nursing child. Decisions regarding breastfeeding while using this medication should involve a discussion with a healthcare provider to balance the mother's clinical need for the drug with the potential risks to the infant.

Available Forms

Trulicity is supplied as a clear, colorless liquid solution for injection under the skin. It is administered via subcutaneous injection in areas such as the abdomen, thigh, or upper arm.

The medication is provided in the following formats:

• Single-dose prefilled pen: A disposable device designed for self-administration.
• Single-dose prefilled syringe: A disposable syringe containing the medication.

Each delivery device is intended for one-time use. After the injection is administered, the device must be disposed of properly in a sharps container.

FDA Approval and Indications

Trulicity (dulaglutide) was first approved by the U.S. Food and Drug Administration (FDA) in 2014. It is indicated for use in adults and children aged 10 years and older with type 2 diabetes to improve blood sugar (glucose) levels, alongside diet and exercise. Additionally, it is approved for adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors to reduce the risk of major adverse cardiovascular events, such as heart attack or stroke.

Boxed Warning

The FDA has issued a boxed warning for Trulicity because dulaglutide has been shown to cause thyroid C-cell tumors in animal studies. It is unknown whether Trulicity causes these tumors in humans. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use this medication.

Safety Communications and Monitoring

The FDA monitors the safety of Trulicity through various reporting systems. Notable regulatory updates and safety signals include:

• Gastrointestinal Concerns: The FDA has identified potential signals of serious risk for ileus (a condition where the bowel does not move properly) through the FDA Adverse Event Reporting System (FAERS).
• Suicidal Ideation Evaluation: The FDA has conducted evaluations regarding reports of suicidal thoughts or actions in patients using GLP-1 receptor agonists. While current reviews have not found a clear link, the agency continues to monitor this potential risk.

Trulicity is not indicated for the treatment of type 1 diabetes or for patients with diabetic ketoacidosis.

How Trulicity Affects Weight

Trulicity (dulaglutide) belongs to a class of medications called GLP-1 receptor agonists. While its primary purpose is to lower blood sugar levels in adults with type 2 diabetes, it often leads to weight loss. This occurs because the medication mimics a hormone that regulates appetite and digestion.

The medication helps with weight management in several ways:

• Increased Fullness: It signals the brain to feel full more quickly after eating.
• Slower Digestion: It slows down the rate at which the stomach empties, which helps you feel satisfied for a longer period.
• Reduced Appetite: Many users report a general decrease in hunger and food cravings.

Clinical Evidence

In clinical trials, people taking Trulicity for type 2 diabetes generally lost more weight than those taking a placebo or certain other diabetes medications. The amount of weight lost often depends on the dosage; higher doses of Trulicity are typically associated with greater weight reduction. However, it is important to note that Trulicity is intended to be used alongside a healthy diet and regular exercise.

Important Considerations

Trulicity is not currently approved by the FDA as a weight-loss drug. It is specifically indicated for improving blood sugar control and reducing the risk of major cardiovascular events in adults with type 2 diabetes. Because weight loss is considered a secondary effect, results can vary significantly from person to person. Some individuals may lose a noticeable amount of weight, while others may see little to no change.